Therapeutic Solutions International, Inc. (OTC:TSOI), announces today the signing of a Letter of Intent to license exclusive rights to a patented adult stem cell for treatment of chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI) within the field of sports and athletics.
The Oceanside, Calif.-based company says the stem cell is unique in that it possesses features of mesenchymal stem cells, however, it outperforms mesenchymal cells in terms of a) enhanced growth factor production; b) augmented ability to secrete exosomes; and c) superior angiogenic and neurogenic ability.
CTE is caused by repetitive concussive/sub-concussive hits to the head sustained over a period of years and is often found in football players. The condition is characterized by memory loss, impulsive/erratic behavior, impaired judgment, aggression, depression, and dementia.
TSOI shares galloped 62% to 0.259 cents, on 20.9 million shares.